32,815 Shares in Omeros Corporation $OMER Acquired by Compass Financial Management LLC

Compass Financial Management LLC purchased a new stake in shares of Omeros Corporation (NASDAQ:OMER) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 32,815 shares of the biopharmaceutical company’s stock, valued at approximately $312,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. State of Wyoming acquired a new position in shares of Omeros in the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Omeros during the 4th quarter worth about $33,000. Assetmark Inc. purchased a new position in shares of Omeros during the 1st quarter valued at about $38,000. Arax Advisory Partners lifted its holdings in Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,894 shares during the period. Finally, International Assets Investment Management LLC boosted its position in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Trading Up 0.3%

OMER stock opened at $19.32 on Tuesday. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.58. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 15.09 and a beta of 2.54. The business’s 50-day moving average is $11.93 and its 200 day moving average is $11.81.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, equities analysts forecast that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at Omeros

In other news, Director Thomas J. Cable sold 15,000 shares of Omeros stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the transaction, the director owned 35,067 shares in the company, valued at $646,986.15. The trade was a 29.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO David J. Borges sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the completion of the transaction, the chief accounting officer owned 5,000 shares in the company, valued at $84,750. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.